Peregrine Pharmaceuticals(NASDAQ:PPHM) shares
climbed 16.37% to $1.35 following a 80% fall in yesterday’s session after the
company announced that Attorney Advertising, Bronstein, Gewirtz & Grossman,
LLC is investigating potential claims on behalf of purchasers of the securities
of Peregrine Pharmaceuticals, Inc., concerning potential violations of federal
securities laws. The discrepancy was made while reviewing trial data in
preparation for a meeting with the U.S. Food and Drug Administration.
Has
PPHM Found The Bottom and Ready To Move Up? Find out Here
Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG) stock
gained 10.78% to $7.50. The company announced that Kenneth A. Berlin, President
and Chief Executive Officer of Rosetta Genomics, will present a corporate
update at the 2012 Aegis Healthcare Conference taking place from September
27-29, 2012 at The Wynn in Las Vegas, Nevada. Mr. Berlin's presentation will
take place on Saturday, September 29th at 10:00 a.m. Pacific time.
Will
ROSG Continue To Move Higher? Get Free Trend Analysis Here
Union Drilling, Inc.(NASDAQ:UDRL) shares climbed
5.68% to $6.48 after UDRL and Sidewinder Drilling Inc. have entered into a
definitive agreement and plan of merger pursuant to which Sidewinder will
acquire all of the outstanding shares of Union Drilling common stock in an
all-cash tender offer valued at approximately $242 million. Under the terms of
the agreement and plan of merger, which has been unanimously approved by Union
Drilling's Board of Directors, Sidewinder's acquisition subsidiary, Fastball
Acquisition, Inc., will commence a cash tender offer to purchase all of the
outstanding shares of Union Drilling for $6.50 per share.
Netflix, Inc.(NASDAQ:NFLX) shares fell 1.03% to
$55.80 after Cantor Fitzgerald initiated coverage on shares of Netflix in a
research note released last week. The firm issued a buy rating and a $70.00
price target on the stock. Separately, Analysts at Macquarie initiated coverage
on shares of Netflix in a research note to investors on September 17. They set
an underperform rating and a $50.00 price target on the stock.
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) shares
increased 3.86% to $0.803 after the company said the European Patent Office,
granted patent for the use of its product, AEZS-130, a ghrelin agonist in
connection to methods and kits for use in the diagnosis of growth hormone
deficiency in Europe, effective September 19, 2012. The company said the patent
would expire on February 19, 2027.
No comments:
Post a Comment